Alpha 2.0
Login Register
» Authors » Adel Ghiaty

Adel Ghiaty

Explore the profile of Adel Ghiaty including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 149
Followers 0
Related Specialties
Chemistry
Biochemistry
Oncology
Top 10 Co-Authors
Ashraf H Bayoumi
Abdelrahman S Mayhoub
Hamada S Abulkhair
Mohamed N Seleem
Haroon Mohammad
Mohamed Hagras
Hany E A Ahmed
Ahmed El-Morsy
Mohamed Alswah
Youssef A Hegazy
Published In
Eur J Med Chem
Bioorg Chem
Bioorg Med Chem Lett
J Med Chem
Mol Divers
Affiliations
Soon will be listed here.
Recent Articles
1.
-Butylphenylthiazoles with an oxadiazole linker: a novel orally bioavailable class of antibiotics exhibiting antibiofilm activity
Kotb A, Abutaleb N, Hagras M, Bayoumi A, Moustafa M, Ghiaty A, et al.
RSC Adv . 2022 May; 9(12):6770-6778. PMID: 35518469
The structure-activity and structure-kinetic relationships of a new -butylphenylthiazole series with oxadiazole linkers were conducted with the objective of obtaining a new orally available antibacterial compounds. Twenty-two new compounds were...
2.
From triazolophthalazines to triazoloquinazolines: A bioisosterism-guided approach toward the identification of novel PCAF inhibitors with potential anticancer activity
El-Shershaby M, Ghiaty A, Bayoumi A, Al-Karmalawy A, Husseiny E, El-Zoghbi M, et al.
Bioorg Med Chem . 2021 Jun; 42:116266. PMID: 34126285
Inhibition of PCAF bromodomain has been validated as a promising strategy for the treatment of cancer. In this study, we report the bioisosteric modification of the first reported potent PCAF...
3.
In vivo- and in silico-driven identification of novel synthetic quinoxalines as anticonvulsants and AMPA inhibitors
Abulkhair H, Elmeligie S, Ghiaty A, El-Morsy A, Bayoumi A, Ahmed H, et al.
Arch Pharm (Weinheim) . 2021 Feb; 354(5):e2000449. PMID: 33559320
The lack of effective therapies for epileptic patients and the potentially harmful consequences of untreated seizure incidents have made epileptic disorders in humans a major health concern. Therefore, new and...
4.
Design, synthesis, and antitumor activity of novel compounds based on 1,2,4-triazolophthalazine scaffold: Apoptosis-inductive and PCAF-inhibitory effects
Turky A, Bayoumi A, Ghiaty A, El-Azab A, Abdel-Aziz A, Abulkhair H
Bioorg Chem . 2020 Jul; 101:104019. PMID: 32615465
The antitumor activity of newly synthesised triazolophthalazines (L-45 analogues) 10-32 was evaluated in human hepatocellular carcinoma (HePG-2), breast cancer (MCF-7), prostate cancer (PC3), and colorectal carcinoma (HCT-116) cells. Compounds 17,...
5.
Novel triazolophthalazine-hydrazone hybrids as potential PCAF inhibitors: Design, synthesis, in vitro anticancer evaluation, apoptosis, and molecular docking studies
Abulkhair H, Turky A, Ghiaty A, Ahmed H, Bayoumi A
Bioorg Chem . 2020 May; 100:103899. PMID: 32454390
Three novel series of triazolophthalazine derivatives bearing hydrazone moiety were designed, synthesized, and evaluated for their anticancer activity against four human cancer cell lines by MTT assay. Six derivatives demonstrated...
6.
Design, synthesis, and molecular docking studies of new [1,2,4]triazolo[4,3-a]quinoxaline derivatives as potential A2B receptor antagonists
Ezzat H, Bayoumi A, Sherbiny F, El-Morsy A, Ghiaty A, Alswah M, et al.
Mol Divers . 2020 Mar; 25(1):291-306. PMID: 32166485
Many shreds of evidence have recently correlated A2B receptor antagonism with anticancer activity. Hence, the search for an efficient A2B antagonist may help in the development of a new chemotherapeutic...
7.
Antimicrobial screening and pharmacokinetic profiling of novel phenyl-[1,2,4]triazolo[4,3-a]quinoxaline analogues targeting DHFR and E. coli DNA gyrase B
Omar A, Alswah M, Ahmed H, Bayoumi A, El-Gamal K, El-Morsy A, et al.
Bioorg Chem . 2020 Feb; 96:103656. PMID: 32062449
A novel series of [1,2,4]triazolo[4,3-a]quinoxaline derivatives of different heteroaromatization members were synthesized. The newly synthesized molecules were explored for their potential antimicrobial activities against a panel of pathogenic organisms. Among...
8.
Phenylthiazoles with tert-Butyl side chain: Metabolically stable with anti-biofilm activity
Kotb A, Abutaleb N, Seleem M, Hagras M, Mohammad H, Bayoumi A, et al.
Eur J Med Chem . 2018 Apr; 151:110-120. PMID: 29605807
A new series of phenylthiazoles with t-butyl lipophilic component was synthesized and their antibacterial activity against a panel of multidrug-resistant bacterial pathogens was evaluated. Five compounds demonstrated promising antibacterial activity...
9.
Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA)
Elsebaei M, Mohammad H, Abouf M, Abutaleb N, Hegazy Y, Ghiaty A, et al.
Eur J Med Chem . 2018 Feb; 148:195-209. PMID: 29459278
The promising activity of phenylthiazoles against multidrug-resistant bacterial pathogens, in particular MRSA, has been hampered by their limited systemic applicability, due to their rapid metabolism by hepatic microsomal enzymes, resulting...
10.
Biphenylthiazole antibiotics with an oxadiazole linker: An approach to improve physicochemical properties and oral bioavailability
Hagras M, Hegazy Y, Elkabbany A, Mohammad H, Ghiaty A, Abdelghany T, et al.
Eur J Med Chem . 2017 Nov; 143:1448-1456. PMID: 29126738
A new series of oxadiazolylbiphenylthiazoles was prepared with the objective of improving the limited solubility of first-generation derivatives while maintaining antibacterial activity against drug-resistant Staphylococcus aureus. Studying the structure-activity relationship...